/

ANIP

ANI Pharmaceuticals, Inc.Pre-market

73.59−0.30 −0.41%USD

NasdaqGM · as of Oct 12, 16:00 ET · 15m delay

Open

73.89

Prev close

73.89

Day range

72.8074.28

52-week range

69.5897.00

Volume

315.78K0.83×

Mkt cap

1.69B

P/E ttm

15.89

Fwd P/E

7.24

EPS ttm

4.63

Div yield

0.00%

Earnings

Aug 7, 2026

From 52w high

−24.13%

Price Chart

Yahoo Finance · delayed

ANIPOct 12, 2026O 74.00H 74.28L 72.80C 73.59−0.30 (−0.41%)Vol 318.50K

SMA 5074.45
SMA 20078.24

1Y change −18.04% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ANIP ANI Pharmaceuticals, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +1.39%
1 month: +4.84%
3 months: −9.24%
6 months: −6.03%
Year to date: −6.78%
1 year: −18.04%

Valuation & ownership

Market cap: 1.69B
Enterprise value: 1.83B
P/E (ttm): 15.89
Forward P/E: 7.24
PEG ratio: 1.83
Price / book: 2.64
Price / sales (ttm): 1.73
EV / EBITDA: 8.72
EPS (ttm): 4.63
EPS (forward): 10.17
Beta (5y monthly): 0.49
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 22.96M
Float: 19.66M
Short % of float: 18.52%
Short ratio (days): 8.36
Held by insiders: 5.42%
Held by institutions: 107.29%
Avg volume (3m): 379.19K
50-day average: 74.45
200-day average: 78.24
52-week change: −18.04%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 50.1
vs 50-day SMA: −1.16%
vs 200-day SMA: −5.94%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 2.89%
Realised vol (20d, ann.): 30.9%
From 52-week high: −24.13%
From 52-week low: +5.76%

ANR

Analyst Consensus

9 analysts

Consensus

Buy

1.78 on a 1 (strong buy) – 5 (sell) scale

Mean target

105.78

+43.74% implied

Low 85.00Median 104.00High 121.00

Recommendation trend

Now7 / 2 / 0
1m ago / 2 /

DES

About ANI Pharmaceuticals, Inc.

Yahoo Finance profile

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 970
Headquarters: Baudette, MN, United States
Website: anipharmaceuticals.com
Officers: Mr. Nikhil Lalwani President, CEO & Director
Mr. Stephen P. Carey Senior VP of Finance & CFO
Ms. Meredith W. Cook J.D. Senior VP, General Counsel & Corporate Secretary
Mr. Christopher K. Mutz Senior VP & Head of Rare Disease

SEAS

Seasonality · ANIP

2007–2026 · monthly returns

Strongest month Jan +8.49%Weakest month Dec −5.70%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	3.7	-9.7	4.1	3.3	-1.2	5.4	-4.3	-7.6	-0.8	1.3			−6.8%
2025	6.1	5.5	8.2	5.8	-17.1	11.1	-2.9	47.6	-2.0	-1.1	-6.3	-7.0	+42.8%
2024	1.2	21.2	2.2	-4.5	-1.7	-1.9	3.2	-3.0	-6.4	-4.0	-0.0	-3.4	+0.3%
2023	11.2	-6.5	-5.1	-5.0	19.7	19.3	-2.4	22.5	-9.8	6.3	-19.3	10.7	+37.1%
2022	-12.3	-7.3	-24.9	5.0	2.5	-1.9	15.4	7.7	-12.9	20.1	8.7	-4.1	−12.7%
2021	-1.7	2.0	24.2	-7.9	3.2	2.0	-3.2	-10.6	8.2	13.9	10.1	12.0	+58.7%
2020	0.5	-22.6	-15.1	-1.8	-22.4	4.1	-8.4	5.9	-10.0	-9.6	16.0	-1.8	−52.9%
2019	19.4	22.4	7.2	0.6	-1.9	18.0	2.9	-22.6	11.3	7.2	-21.1	0.1	+37.0%
2018	4.2	-4.6	-9.1	1.9	6.6	5.5	0.2	-13.1	-2.9	-14.2	14.5	-19.0	−30.1%
2017	-0.3	-2.3	-16.2	9.3	-19.3	7.1	4.1	-1.5	9.4	10.6	22.4	-9.4	+6.3%
2016	-29.1	3.3	1.8	35.1	19.1	3.1	8.6	-1.4	11.1	-10.0	-1.3	2.9	+34.3%
2015	-0.7	20.4	-7.1	-2.5	-17.4	23.2	14.5	-31.3	-19.0	5.9	4.7	3.0	−20.0%
2014	10.5	36.5	3.5	-0.8	2.4	8.1	-25.6	14.5	-3.6	20.1	59.3	4.2	+180.8%
2013	13.0	-5.8	-10.7	-3.4	8.0	-18.0	15.7	2.3	37.6	4.9	39.0	40.9	+172.1%
2012	30.0	18.5	-11.7	-19.1	-16.4	-7.6	-42.0	0.0	27.7	-34.9	9.8	-8.9	−59.0%
2011	13.4	15.6	-7.9	17.7	34.3	-12.1	7.3	-11.2	-13.0	16.2	-9.4	-79.2	−69.5%
2010	5.5	9.8	6.5	31.3	-16.2	-10.7	-8.5	-18.6	28.2	-10.7	-2.0	11.6	+13.1%
2009	60.0	-12.5	-5.7	58.3	0.5	-4.8	-8.5	5.5	2.6	-23.2	-3.9	-0.7	+45.0%
2008	5.8	-13.8	32.2	-13.6	1.3	18.8	18.4	-7.8	-5.4	-33.9	-44.6	-44.1	−73.5%
2007	24.5	26.7	36.6	17.3	-2.6	-7.0	-12.9	5.1	0.0	3.3	-24.7	-16.2	+36.5%

INSD

Insider Activity · ANIP

Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

35.1K shares

Sells, 6 months

109.7K shares

Net shares

−74.6K

Net change in insider shares

−6.00%

Date	Insider	Transaction	Shares	Value
Sep 28, 2026	Carey Stephen P.Chief Financial Officer	Sale at price 73.00 per share.	2.9K	$208.05K
Sep 14, 2026	Lalwani Nikhil SureshChief Executive Officer	Sale at price 71.00 per share.	5.4K	$383.40K
Sep 13, 2026	Cook MeredithGeneral Counsel	Sale at price 70.79 per share.	500	$35.40K
Sep 10, 2026	Thoma JeanneDirector	Sale at price 71.53 per share.	1K	$71.53K
Aug 30, 2026	Carey Stephen P.Chief Financial Officer	Sale at price 72.80 per share.	2.9K	$207.48K
Aug 24, 2026	Lalwani Nikhil SureshChief Executive Officer	Sale at price 74.30 per share.	5.4K	$401.22K
Aug 18, 2026	Gosebruch Henry O.Director	Stock Award(Grant) at price 0.00 per share.	6.7K	—
Aug 12, 2026	Cook MeredithGeneral Counsel	Sale at price 75.48 per share.	500	$37.74K
Aug 9, 2026	Gutwerg OriOfficer	Sale at price 77.00 per share.	3.2K	$243.47K
Jul 28, 2026	Carey Stephen P.Chief Financial Officer	Sale at price 81.36 per share.	2.9K	$231.88K
Jul 12, 2026	Cook MeredithGeneral Counsel	Sale at price 81.84 per share.	500	$40.92K
Jul 1, 2026	Carey Stephen P.Chief Financial Officer	Sale at price 86.00 per share.	3.3K	$284.92K
Jul 1, 2026	Carey Stephen P.Chief Financial Officer	Conversion of Exercise of derivative security at price 49.51 per share.	3.3K	$164.03K
Jun 28, 2026	Carey Stephen P.Chief Financial Officer	Sale at price 84.12 per share.	2.9K	$239.74K
Jun 11, 2026	Cook MeredithGeneral Counsel	Sale at price 82.03 per share.	500	$41.02K
Jun 7, 2026	Haughey Thomas JDirector	Sale at price 80.88 per share.	2K	$161.76K
Jun 4, 2026	Carey Stephen P.Chief Financial Officer	Sale at price 80.00 per share.	3.3K	$264.96K
Jun 4, 2026	Carey Stephen P.Chief Financial Officer	Conversion of Exercise of derivative security at price 49.51 per share.	3.3K	$163.98K
May 20, 2026	Pera Antonio RDirector	Stock Award(Grant) at price 0.00 per share.	4.4K	—
May 20, 2026	Haughey Thomas JDirector	Stock Award(Grant) at price 0.00 per share.	4.4K	—

ANIP

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ANIP

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About ANI Pharmaceuticals, Inc.

Seasonality · ANIP

Insider Activity · ANIP

Congress Trades · ANIP

Congress Trades · ANIP

Insider Activity · ANIP

Seasonality · ANIP

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About ANI Pharmaceuticals, Inc.

Financial Snapshot

Earnings & Dividends

News